CytoDyn, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cytodyn.com
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06699836
- Locations
- πΊπΈ
Quest Clinical Research, San Francisco, California, United States
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
- Conditions
- CCR5Microsatellite StableMetastaticColorectal Cancer
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT05730673
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
- Conditions
- HIV-1-infection
- Interventions
- Drug: PRO 140 700Drug: PRO 140 350Drug: PRO 140 525
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05271370
- Locations
- πΊπΈ
Quest Clinical Research, San Francisco, California, United States
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
- Conditions
- Coronavirus Disease 2019
- Interventions
- Drug: Placebos
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04678830
- Locations
- πΊπΈ
Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States
πΊπΈArthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04521114
- Locations
- πΊπΈ
Southern California Research Center, Coronado, California, United States
πΊπΈFloridian Clinical Research, Miami Lakes, Florida, United States
πΊπΈCenter for Advanced Research & Education, Gainesville, Georgia, United States
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04504942
- Locations
- πΊπΈ
Quest Clinical Research, San Francisco, California, United States
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 394
- Registration Number
- NCT04347239
- Locations
- πΊπΈ
Advanced Cardiovascular, LLC, Alexander City, Alabama, United States
πΊπΈOhio Health, Columbus, Ohio, United States
πΊπΈSt. Barnabas, Livingston, New Jersey, United States
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
- Conditions
- Coronavirus Disease 2019
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT04343651
- Locations
- πΊπΈ
Eisenhower Health, Rancho Mirage, California, United States
πΊπΈUniversity of California, Los Angeles, Los Angeles, California, United States
πΊπΈOhio Health, Columbus, Ohio, United States
A Compassionate Use Study of Leronlimab in Breast Cancer
- Conditions
- Metastatic Triple-Negative Breast Carcinoma
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT04313075
PRO 140 in Treatment-Experienced HIV-1 Subjects
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03902522
- Locations
- πΊπΈ
CD02_OpenLabel Investigational Site, Spokane, Washington, United States